Drug Trial Radar · NCT07139431
A Study of [89Zr]-Oxine-NCR100 Injection for the Cellular Distribution
Last checked: Nov 19, 2026Latest source record: Aug 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
6
Planned (sponsor's estimate)
Start
Aug 29, 2025
Primary completion
Mar 6, 2026
Study completion Apr 21, 2028
Sponsor
- Lead sponsor
- Nuwacell Biotechnologies Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 40 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This clinical study is to evaluate the biodistribution of \[89Zr\]-Oxine-NCR100 injection in subjects with knee osteoarthritis after local injection and the kinetic behavior characteristics of zirconium-labeled cells at the injection site and various organs or tissues. It is a single-dose, open-label study in adult KOA subjects.
Conditions
- KOA
Interventions
NCR100Biological
Subjects will receive a single injection of NCR100
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Standardized Uptake Values (SUV) and %IDTime frame: Day2, Day8,Day12,and Day22
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.